Moleculin Biotech News

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $8

Moomoo NewsNov 12 13:31 ET

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $8

Moomoo NewsNov 12 08:35 ET

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsAug 2 14:31 ET

Buy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued Shares

TipRanksAug 2 14:27 ET

Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), MiNK Therapeutics (INKT)

TipRanksMay 14 10:55 ET

Moleculin Biotech Analyst Ratings

BenzingaApr 12 12:24 ET

Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating

MT NewswiresMar 26 10:17 ET

Moleculin Biotech Analyst Ratings

BenzingaMar 26 09:24 ET

HC Wainwright & Co. Initiates Coverage On Moleculin Biotech With Buy Rating, Announces Price Target of $3

BenzingaDec 14, 2023 06:06 ET

Moleculin Biotech Analyst Ratings

BenzingaDec 14, 2023 06:05 ET

Oppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)

TipRanksNov 30, 2023 07:26 ET

Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Vir Biotechnology (VIR)

TipRanksNov 14, 2023 12:20 ET

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Moleculin Biotech (MBRX)

TipRanksNov 7, 2023 15:30 ET

Maxim Group Reaffirms Their Buy Rating on Moleculin Biotech (MBRX)

TipRanksMay 12, 2023 12:26 ET

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Phibro Animal Health (PAHC) and Moleculin Biotech (MBRX)

TipRanksMay 4, 2023 08:30 ET

Roth MKM Maintains Buy on Moleculin Biotech, Maintains $16 Price Target

BenzingaApr 18, 2023 18:07 ET

Analysts' Top Healthcare Picks: Moleculin Biotech (MBRX), Biomea Fusion (BMEA)

TipRanksMar 25, 2023 01:51 ET

Maxim Group Sticks to Its Buy Rating for Moleculin Biotech (MBRX)

TipRanksMar 24, 2023 13:06 ET

Oppenheimer Reiterates Outperform on Moleculin Biotech, Maintains $5 Price Target

BenzingaMar 24, 2023 08:47 ET

Roth MKM Sticks to Their Buy Rating for Moleculin Biotech (MBRX)

TipRanksMar 2, 2023 11:11 ET